- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05964049
pBFS Guided rTMS Therapy for Treatment-resistant Obsessive-Compulsive Disorder
Personalized Brain Functional Sectors (pBFS) Guided rTMS Therapy for Treatment-resistant Obsessive-Compulsive Disorder: A Randomized, Double-Blind, Sham-controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In 2018, rTMS received approval from the U.S. Food and Drug Administration (FDA) for the treatment of OCD. Based on randomized clinical trials, researchers have observed significant variations in the intervention effects when targeting the dorsolateral prefrontal cortex (DLPFC), which is a large region with different subregions and functional connections to other areas across multiple functional networks. Precise targeting of neural circuitry related to OCD symptoms is crucial for effective intervention. The ventrolateral prefrontal cortex and insula are key components of the OCD functional circuitry within the ventral attention/salience network. However, stimulating these brain regions with TMS is challenging, and patients often have a low tolerance. Previous studies have found that effective targets for various interventions used in psychiatric disorders are located within the same functional circuitry. Therefore, in this study, The investigator employed the pBFS technique to precisely locate the DLPFC subregions within the ventral attention/salience network. The investigator hypothesizes that rTMS intervention targeting the DLPFC guided by pBFS will significantly alleviate clinical symptoms in treatment-resistant OCD patients.
After being informed about the study and potential risks. All patients giving written informed consent will undergo a screening period to determine eligibility for study entry. At week 0, patients who meet the eligibility requirements will be randomized in a double-blind manner in a 2:1 ratio to the active rTMS group, or sham-control group. Then all participants will undergo a 15-day (3 weeks, treatment on weekdays) rTMS modulation. After treatment, 15-, 30-, 60-, and 90-day follow-up visits will occur. Participants will keep a stable treatment regimen during the intervention and the first-month follow-up.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Meiling Li, Ph.D.
- Phone Number: 010-80726688
- Email: meilingli@cpl.ac.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Recruiting
- Peking University Six Hospital
-
Contact:
- Jinmin Liao
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Hospitalized/outpatient patients aged 18-65 years (inclusive), male or female.
- Meet the diagnostic criteria of DSM-5(Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) for obsessive-compulsive disorder, and currently experiencing a first or recurrence episode.
- Total Y-BOCS score ≥20 and total HAMD score <17 before randomization.
- Before randomization, patients must have received a minimum of 2 months of maintenance treatment with SSRI medication prior to randomization, or have undergone maintenance CBT treatment with inadequate response to SSRI medication (less than 50% symptom improvement), or have previously shown inadequate response (less than 50% symptom improvement) to at least one trial of SSRI medication or cognitive-behavioral therapy. Patients currently taking medication should have been on a stable dose for 8 weeks.
- Voluntarily participate in the trial and sign informed consent. Able to comply with the planned visit, examination and treatment plan, and other study procedures.
Exclusion Criteria:
- Meet DSM-5 diagnostic criteria for other mental disorders (such as schizophrenia, schizoaffective disorder, post-traumatic stress disorder, bipolar disorder, and secondary depression, etc.);
- Patients with a cardiac pacemaker, cochlear implant, or other metal foreign body and any electronic equipment implanted in the body, patients with claustrophobia and other contraindications to magnetic resonance scanning, and patients with contraindications to rTMS treatment;
- History of epilepsy (presence of at least 2 uninduced seizures more than 24 hours apart, or diagnosis of the epileptic syndrome, or seizures within the past 12 months); Or currently received medications or other treatments that will lower the seizure threshold;
- History of ECT, rTMS, light therapy within 3 months;
- Patients with organic brain diseases (such as ischemic stroke, cerebral hemorrhage, brain tumor, etc.) and a history of severe brain trauma as judged by the researcher;
- Patients with serious or unstable diseases of the cardiovascular, liver, kidney, blood, endocrine, neurological system, and other systems or organs.
- Female of childbearing potential who plans to become pregnant during the trial. Female that is pregnant or breastfeeding.
- Substance abuse or dependence (including alcohol, drugs, and other psychoactive substances) in the past 6 months.
- First-degree relatives have bipolar affective disorder and schizophrenia.
- There is a significant risk of suicide (MADRS item 3 ≥ 3).
- Difficulty or inability to engage in normal communication, understand or follow instructions, and cooperate with treatment and evaluators.
- Patients in any clinical trials of other drugs or physical therapy ( DBS, ECT, rTMS) within 1 month before the screening
- Investigators think that was inappropriate to participate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: active rTMS treatment
5 sessions of active rTMS would be delivered to the left DMPFC daily, with a session of 1800 pulse and inter-session interval of 20 min.
|
Participants will receive 5 sessions per day of 1800 pulses per session, lasting for 15 days.
Individualized targets will be generated using the pBFS method.
|
Sham Comparator: sham control
5 sessions of sham rTMS would be delivered to the left DMPFC daily, with a session of 1800 pulse and inter-session interval of 20 min.
|
The parameters in the sham arms are the same as the active stimulation groups.
Stimulation was delivered by the same device as the active group fitted with a sham coil.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
response rates estimated using Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
Time Frame: Baseline, Day 15(immediate post-treatment), 15- and 30-day post-treatment
|
The Y-BOCS is a validated instrument stratifying the severity of obsessive episodes.
This validated questionnaire was used to assess the response rate and remission rate of obsessive episodes.
The response is defined as a symptom improvement of ≥35% on Y-BOCS;
|
Baseline, Day 15(immediate post-treatment), 15- and 30-day post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
remission rates estimated using Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
Time Frame: Baseline, Day 15(immediate post-treatment), 15- and 30-day post-treatment
|
Remission was defined as a score <8.
|
Baseline, Day 15(immediate post-treatment), 15- and 30-day post-treatment
|
Partial response rates estimated using Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
Time Frame: Baseline, Day 15(immediate post-treatment), 15- and 30-day post-treatment
|
Partial response is defined as a symptom 35% ≥ improvement ≥25% on Y-BOCS
|
Baseline, Day 15(immediate post-treatment), 15- and 30-day post-treatment
|
cognitive change in stroop
Time Frame: Baseline, Day 15(immediate post-treatment)
|
The Stroop test can be used to measure a person's selective attention capacity and skills, processing speed, and alongside other tests to evaluate overall executive processing abilities
|
Baseline, Day 15(immediate post-treatment)
|
cognitive change in Hopkins verbal learning test(immediate recall)
Time Frame: Baseline, Day 15(immediate post-treatment)
|
The Hopkins Verbal Learning Test (HVLT-R) is one such assessment that consists of memorization of a list of words to test the ability to recall immediately after memorization
|
Baseline, Day 15(immediate post-treatment)
|
cognitive change in Trail-Making Test
Time Frame: Baseline, Day 15(immediate post-treatment)
|
The test can provide information about visual search speed, scanning, speed of processing, mental flexibility, and executive functioning
|
Baseline, Day 15(immediate post-treatment)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Hesheng Liu, Ph.D., Changping Laboratory
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CPLOCDDLPFC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obsessive-Compulsive Disorder
-
Anne Katrine PagsbergCopenhagen Trial Unit, Center for Clinical Intervention Research; Danish Research...Active, not recruitingObsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceDenmark
-
Baylor College of MedicineRecruitingObsessive-Compulsive Disorder | Cognitive Behavioral Therapy | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceUnited States
-
Chaim HuijserLevvelRecruitingObsessive-Compulsive Disorder | Anxiety Disorders and Symptoms | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceNetherlands
-
Stanford UniversityCompletedObsessive Compulsive DisorderUnited States
-
NYU Langone HealthCompletedObsessive Compulsive DisorderUnited States
-
Massachusetts General HospitalActive, not recruitingObsessive Compulsive DisorderUnited States
-
Boston University Charles River CampusCompletedObsessive Compulsive DisorderUnited States
-
Butler HospitalNational Institute of Mental Health (NIMH)CompletedObsessive Compulsive DisorderUnited States
-
Karolinska InstitutetCompletedObsessive Compulsive DisorderSweden
-
Roseli ShavittCompleted
Clinical Trials on sham rTMS treatment
-
Changping LaboratoryNot yet recruitingMajor Depressive Disorder | Treatment Resistant DepressionChina
-
Changping LaboratoryWest China Hospital; The Second Affiliated Hospital of Xinxiang Medical University and other collaboratorsRecruitingMajor Depressive Disorder | Treatment Resistant DepressionChina
-
Changping LaboratoryNot yet recruitingObsessive-Compulsive Disorder | OCD
-
University of ManitobaUnknownAlzheimer's DiseaseCanada, Australia
-
Sunnybrook Health Sciences CentreRecruiting
-
Wave NeuroscienceCompleted
-
Wave NeuroscienceTexas A&M University; GilpinPhillips BIOMED, LLC; Peachtree BioResearch SolutionsRecruitingTraumatic Brain Injury | PostTraumatic Stress Disorder | Postconcussive SymptomsUnited States
-
Stanford UniversityNational Institute of Mental Health (NIMH); The Dana FoundationCompleted
-
Zhujiang HospitalUnknown
-
Masarykova UniverzitaBrno University Hospital; Masaryk UniversityRecruitingBorderline Personality DisorderCzechia